Derapi | $7,000,000 | (Feb 4, 2026)
MaiaEdge | $20,000,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
Graici | $7,500,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
ecovia I bio | Undisclosed Amount | (Feb 4, 2026)
Prenosis | $20,000,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)